Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1993-11-09
1998-12-22
Kight, John
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514467, 514 49, 544317, 549429, 536 285, 536 2851, 536 2852, A61K 31505, C07D23902
Patent
active
058520279
DESCRIPTION:
BRIEF SUMMARY
The invention described herein includes a stereoselective synthesis of 1,3-dioxolane nucleosides, and antivirally active 1,3-dioxolane nucleosides.
In 1981, acquired immune deficiency syndrome (AIDS) was identified as a disease that severely compromises the human immune system, and that almost without exception leads to death. In 1983, the etiological cause of AIDS was determined to be the human immunodeficiency virus (HIV). In December, 1990, the World Health Organization estimated that between 8 and 10 million people worldwide were infected with HIV, and of that number, between 1,000,000 and 1,400,000 were in the United States.
In 1985, it was reported that the synthetic nucleoside 3'-azido-3'-deoxythymidine (AZT) inhibits the replication of human immunodeficiency virus type 1. Since then, a number of other synthetic nucleosides, including 2',3'-dideoxyinosine (DDI), 2',3'-dideoxycytidine (DDC), 3'-fluoro-3'-deoxythymidine (FLT), 2',3'-dideoxy,2',3'-didehydrothymidine (D4T), and 3'-azido-2',3'-dideoxyuridine (AZDU), have been proven to be effective against HIV. A number of other 2',3'-dideoxynucleosides have been demonstrated to inhibit the growth of a variety of other viruses in vitro. It appears that, after cellular phosphorylation to the 5'-triphosphate by cellular kinases, these synthetic nucleosides are incorporated into a growing strand of viral DNA, causing chain termination due to the absence of the 3'-hydroxyl group.
Both DDC and D4T are potent inhibitors of HIV replication with activities comparable (D4T) or superior (DDC) to AZT. However, both DDC and D4T are not efficiently converted to the corresponding 5'-triphosphates in vivo and are resistent to deaminases and phosphorylases. Both compounds are also toxic.
The success of various 2',3'-dideoxynucleosides in inhibiting the replication of HIV in vivo or in vitro has led a number of researchers to design and test nucleosides that substitute a heteroatom for the carbon atom at the 3'-position of the nucleoside. Norbeck, et al., disclose that (referred to below as (.+-.)-dioxolane-T or DOT, see FIG. 2), a 1,3 dioxolane nucleoside, exhibits a modest activity against HIV (EC.sub.50 of 20 .mu.m in ATH8 cells), and is not toxic to uninfected control cells at a concentration of 200 .mu.m. Tetrahedron Letters 30 (46), 6246, (1989). In light of the fact that this compound exhibits efficacy against HIV and has very low toxicity, it is desirable to develop suitable synthetic protocols for preparing a wide variety of analogs and isomers of this compound.
To market a nucleoside for pharmaceutical purposes, it must not only be efficacious with low toxicity, it must also be cost effective to manufacture. An extensive amount of research and development has been directed toward new, low cost processes for large scale nucleoside production.
2',3'-Dideoxynucleosides are currently prepared by either of two routes; derivatization of an intact nucleoside or condensation of a derivatized sugar moiety with a heterocyclic base. Although there are numerous disadvantages associated with obtaining new nucleoside analogues by modifying intact nucleosides, a major advantage of this approach is that the appropriate absolute stereochemistry has already been set by nature. Obviously, this approach cannot be used in the production of nucleosides that contain either nonnaturally occurring bases or nonnaturally occurring carbohydrate moieties (and which therefore are not prepared from intact nucleosides), such as 1,3-dioxolane nucleosides.
When condensing a carbohydrate-like moiety such as a 1,3-dioxolane with a heterocyclic base to form a synthetic nucleoside, a nucleoside is produced that has two chiral centers (at the C1' and C4' positions, see FIG. 1), and thus exists as a diastereomeric pair. Each diastereomer exists as a set of enantiomers. Therefore, the product is a mixture of four enantiomers. It is often found that nucleosides with nonnaturally-occurring stereochemistry in either the C1' or the C4'-positions are less active than the same nucleoside with the stereochem
REFERENCES:
patent: 4000137 (1976-12-01), Dvonch et al.
patent: 4140761 (1979-02-01), Gerin et al.
patent: 4336381 (1982-06-01), Nagata et al.
patent: 4601987 (1986-07-01), Klibanov et al.
patent: 4732853 (1988-03-01), Whitesides et al.
patent: 4861759 (1989-08-01), Mitsuya et al.
patent: 4879277 (1989-11-01), Mitsuya et al.
patent: 4900828 (1990-02-01), Belica et al.
patent: 4916122 (1990-04-01), Chu et al.
patent: 4923810 (1990-05-01), Walts et al.
patent: 4963533 (1990-10-01), de Clercq et al.
patent: 5011774 (1991-04-01), Farina et al.
patent: 5032523 (1991-07-01), Amano et al.
patent: 5041449 (1991-08-01), Belleau et al.
patent: 5041499 (1991-08-01), Belleau et al.
patent: 5047407 (1991-09-01), Belleau et al.
patent: 5059690 (1991-10-01), Zahler et al.
patent: 5071983 (1991-12-01), Koszalka et al.
patent: 5084387 (1992-01-01), Patel et al.
patent: 5106750 (1992-04-01), Wong et al.
patent: 5179104 (1993-01-01), Chu et al.
patent: 5185437 (1993-02-01), Koszalka et al.
patent: 5204466 (1993-04-01), Liotta et al.
patent: 5210085 (1993-05-01), Liotta et al.
patent: 5234913 (1993-08-01), Furman, Jr. et al.
patent: 5248776 (1993-09-01), Chu et al.
patent: 5270315 (1993-12-01), Belleau et al.
patent: 5276151 (1994-01-01), Liotta et al.
patent: 5444063 (1995-08-01), Schinazi
patent: 5466806 (1995-11-01), Belleau et al.
patent: 5486520 (1996-01-01), Belleau et al.
patent: 5532246 (1996-07-01), Belleau et al.
patent: 5538975 (1996-07-01), Dionne
patent: 5539116 (1996-07-01), Liotta et al.
patent: 5587480 (1996-12-01), Belleau et al.
patent: 5618820 (1997-04-01), Dionne
U.S. application No. 07/686,617, Cheng et al., filed Jul. 1996.
U.S. application No. 07/718,806, Cheng, filed Jun. 1991.
U.S. application No. 07/785,545, Cheng, filed Oct. 1991.
Abobo, et al., "Pharmacokinetics of 2',3'-Dideoxy-5-fluoro-3'-thiacytidine in Rats," J. of Pharmaceutical Sciences, 83(1):96-99 (1994). Month of Publication data is unavailable. Issue No. has been included when possible.
Agranat and Biedermann, "Intellectual Property and Chirality: Patentability of Enantiomers of Racemic Drugs in a Racemic Switch Scenario,"8th Chirality Conference, Edinburgh, UK (Jul. 2, 1996).
Baschang, et al., "The enantiomers of 1.beta.-adenyl-2.alpha.-hydroxy-3.beta.-(hydroxymethyl)cyclobutane," Tetrahedron:Asymmetry, 3(2):193-6 (1992), Abstr. Only. Month of Publication data is unavailable. Issue No. has been included when possible.
Chu, et al., "Synthesis and Anti-HIV and Anti-HBV Activity of Enantiomerically Pure Oxathiolane Nucleosides," Antiviral Research, 17(S1):44 (1992). Month of Publication data is unavailable. Issue No. has been included when possible.
Chu, et al., "Synthesis and Biological Evaluation of D-(2S) and L-(2R)-1,3-Oxathiolanyl-and D-(2R)-and L-(2S)-1,3-Dioxolanyl-Nucleosides as Anti-HIV and Anti-HBV Agents," Antiviral Research, 20(S1):146 (1993), Abstr No. 192. Month of Publication data is unavailable. Issue No. has been included when possible.
Condreay, et al., "Evaluation of the Potent Anti-Hepatitis B Virus Agent Novel In Vivo Model," Antimicrobial Agents and Chemotherapy, 616-619 38 (3), (Mar. 1994). Month of Publication data is unavailable. Issue No. has been included when possible.
Connolly and Hammer, "Minireview: Antiretroviral Therapy: Reverse Transcriptase Inhibition," Antimicrobial Agents and Chemotherapy, 36(2):245-254 (1992). Month of Publication data is unavailable. Issue No. has been included when possible.
Feorino et al., "Prevention of activation of HIV-1 by antiviral agents in OM-10.1 cells," Antiviral Chem. & Chemotherapy, 4(1):55-63 (1993). Month of Publication data is unavailable. Issue No. has been included when possible.
Frick, et al., "Pharmacokinetics, Oral Bioavailability, and Metabolic Disposition in Rats of Nucleoside Analog Active against Human Immunodeficiency Virus and Hepatitis B Virus," Antimicrobial Agents and Chemotherapy, 38(12):2722-2724 (1994). Month of Publication data is unavailable. Issue No. has been included when possible.
Furman, et al.,
Choi Woo-Baeg
Liotta Dennis C.
Schinazi Raymond F.
Crane L. Eric
Emory University
Haley Jacqueline
Kight John
Knowles Sherry M.
LandOfFree
Antiviral 1,3-dioxolane nucleoside analogues does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antiviral 1,3-dioxolane nucleoside analogues, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antiviral 1,3-dioxolane nucleoside analogues will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2047954